Daily Management Review

89% Efficacy Shown By Novavax Cobid-19 Vaccine In UK Trials


89% Efficacy Shown By Novavax Cobid-19 Vaccine In UK Trials
Trial results of a new virus against Covid-19 in the United Kingdom have showed an efficacy rate of 89.3 per cent. This new vaccine called Novavax is the first one that that has shown its effectiveness against the new virus variant found in the UK in trials. 
Welcoming the "good news", UK prime minster Boris Johnson said that that new vaccine would be assessed by the medicines regulator of the country. 60 million doses of the new vaccine have been secured by the UK already and the vaccine will be manufactured in Stockton-on-Tees north-east England. 
The government said that of the vaccine is approved for use by the Medicines and Healthcare Products Regulatory Agency (MHRA), it would be expected to be delivered in the second half of this year.
Three coronavirus vaccines for emergency use have already been approved in the UK which includes vaccines from the Oxford University and AstraZeneca, another by Pfizer and BioNTech, and a third from vaccine firm Moderna.
The two dose Novavax vaccine was found to have exhibited 89.3 per cent efficiency in stopping an inoculated person from being infected with Covid-19 after results from Phase 3 clinical trials in the UK were analysed.  More than 15,000 people aged between 18 and 84 years were enrolled for the Phase 3 clinical trial which is typically the last phase of trials for any vaccine before they are reviewed and approved by a regulator. Those participating in the Novavax Phase 3 trials also comprised of 27 per cent of people who were over the age of 65 years, said the United States based pharma company that developed the vaccine.
The vaccine was also found to be 60 per cent effective among those without HIV in trials of Novavax in South Africa where most of the cases in the trials were infections caused by the effective among those without HIV.
The results of the UK trials were described as "spectacular" and "as good as we could have hoped" by Stan Erck, chief executive of Novavax. Erck added that the trial result of the vaccine in South Africa was "above people's expectations".
The company would be able to set up and make operational the manufacturing plant in Stockton-on-Tees by March or April this year as the company was hopeful that it would get approval for use of the vaccine by that time from the MHRA of the UK.
If approved, the new vaccine would be "another weapon in our arsenal to beat this awful virus", said UK’s health Secretary Matt Hancock. "I'm proud the UK is at the forefront of another medical breakthrough" he added while thanking researches and volunteers who took part in the trials.
The findings of the clinical trials were "enormously exciting findings" specifically because of the efficacy rate of the vaccine against the UK variant of the virus, said Prof Paul Heath, chief investigator of the UK Novavax trial.